Raymond Goodrich

Goodrich’s research program is focused on using new methods to stimulate immune response in patients with cancer and to prevent infectious diseases. A clinical application of new technology developed in his lab is for treatment of patients with advanced stage ovarian cancer. In addition, his group is focused on developing methods to generate new vaccine candidates for infectious diseases in humans and animals. The current program of work includes research on new vaccine formulations for SARS-CoV-2, Tuberculosis, Influenza and African Swine Fever, using a technology platform for production of vaccines invented in collaboration with colleagues at Colorado State University. Goodrich served as the Executive Director of the Infectious Disease Research Center at Colorado State University from 2016 to 2023. Prior to this, he spent 30 years in the private sector, leading research groups in the development of medical devices and products for collection, processing and preservation of blood and tissues and for the prevention of disease transmission by blood products. He has been the co-founder of four start-up companies. Goodrich is the recipient of an honorary Order of Military Medical Merit (2018) and the CSU award for Innovative Excellence (2021). He serves as a member of the HHS Advisory Committee on Blood and Tissue Safety and Availability and the advisory board for the School of Biomedical Engineering at Colorado State University. He is also a member of the Association for the Advancement of Blood and Biotherapies public policy and strategy committee.